JANX Quote, Financials, Valuation and Earnings

Merck & Co., Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of 33.68%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Merck & Co., Inc.'s return on equity of 39.63%.

Janux Therapeutics, Inc. has a consensus price target of $66.24, signalling upside risk potential of 303.87%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.92 which suggests that it could grow by 4.99%. Given that Janux Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.21% to investors and pays a quarterly dividend of $0.81 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Janux Therapeutics, Inc.'s net income of -$24.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 99.45x versus 3.98x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -132.36%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Syndax Pharmaceuticals, Inc.'s return on equity of -136.36%.

Janux Therapeutics, Inc. has a consensus price target of $66.24, signalling upside risk potential of 303.87%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.31 which suggests that it could grow by 99.13%. Given that Janux Therapeutics, Inc. has higher upside potential than Syndax Pharmaceuticals, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Syndax Pharmaceuticals, Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.361%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Syndax Pharmaceuticals, Inc. quarterly revenues of $45.9M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Syndax Pharmaceuticals, Inc.'s net income of -$60.7M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 99.45x versus 15.26x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -360.68%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Janux Therapeutics, Inc. has a consensus price target of $66.24, signalling upside risk potential of 303.87%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 1.85%. Given that Janux Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.807%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 47.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 99.45x versus 8.81x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics, Inc. has a net margin of -243.13% compared to Janux Therapeutics, Inc.'s net margin of -2734.45%. Janux Therapeutics, Inc.'s return on equity of -10.94% beat Entrada Therapeutics, Inc.'s return on equity of -26.01%.

Janux Therapeutics, Inc. has a consensus price target of $66.24, signalling upside risk potential of 303.87%. On the other hand Entrada Therapeutics, Inc. has an analysts' consensus of $16.50 which suggests that it could grow by 62.4%. Given that Janux Therapeutics, Inc. has higher upside potential than Entrada Therapeutics, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Entrada Therapeutics, Inc..

Janux Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Janux Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics, Inc. pays -- of its earnings as a dividend. Entrada Therapeutics, Inc. pays out -- of its earnings as a dividend.

Janux Therapeutics, Inc. quarterly revenues are $10M, which are larger than Entrada Therapeutics, Inc. quarterly revenues of $1.6M. Janux Therapeutics, Inc.'s net income of -$24.3M is higher than Entrada Therapeutics, Inc.'s net income of -$44.1M. Notably, Janux Therapeutics, Inc.'s price-to-earnings ratio is -- while Entrada Therapeutics, Inc.'s PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics, Inc. is 99.45x versus 6.89x for Entrada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.